ScholarIQanswers from OpenAlex
Cancer Center of Kansas
InstitutionResearch output, impact & collaborations
Cancer Center of Kansas is a institution indexed in ScholarIQ from OpenAlex.
What is known about Cancer Center of Kansas?
ScholarIQrecord summary
Cancer Center of Kansas is a research organisation in Wichita, US. OpenAlex records 506 works and 54,049 citations for it. 102 researchers list it as their most recent affiliation.
How many works does Cancer Center of Kansas have?
ScholarIQindexed works
Cancer Center of Kansas has 506 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Cancer Center of Kansas have?
ScholarIQcitation count
Cancer Center of Kansas has 54,049 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Cancer Center of Kansas?
ScholarIQresearcher count
Cancer Center of Kansas has 102 researchers in the ScholarIQ index.
What is the average h-index at Cancer Center of Kansas?
ScholarIQavg h-index
Cancer Center of Kansas has an average h-index of 81 in OpenAlex.
What is the ROR of Cancer Center of Kansas?
ScholarIQror
The ROR for Cancer Center of Kansas is on the source record.
What is the OpenAlex record for Cancer Center of Kansas?
ScholarIQopenalex
The OpenAlex for Cancer Center of Kansas is on the source record.
Who are the most-cited researchers behind Cancer Center of Kansas?
ScholarIQtop researchers by citations
What are the most-cited papers on Cancer Center of Kansas?
ScholarIQmost cited works
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela Klein, James N. Ingle, Norman Wolmark
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
Thomas M. Habermann, Edie Weller, Vicki A. Morrison, Randy D. Gascoyne, Peter A. Cassileth, Jeffrey Cohn, Shaker R. Dakhil, Bruce A. Woda, Richard I. Fisher, B. A. Peterson, Sandra J. Horning
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
Charles L. Loprinzi, John W. Kugler, Jeff A Sloan, James A. Mailliard, Beth LaVasseur, Debra L. Barton, Paul J. Novotny, Shaker R. Dakhil, Kate Rodger, Teresa A. Rummans, Bradley J. Christensen
How much of the research on Cancer Center of Kansas is open access?
ScholarIQopen access share
60%OPEN ACCESS